A century of pneumococcal vaccination research in humans

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 15-24

  Grabenstein, J D ^a   Klugman, K P ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiserum; History; Pneumococcal vaccine; Serum therapy; Streptococcus pneumoniae

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; DIPHTHERIA ANTIBODY; IMOVAX PNEUMO 14; PLAGUE VACCINE; PNEUMOBACTERIN; PNEUMOCOCCUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESEARCH; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFLUENZA; LOBAR PNEUMONIA; MEDICAL RESEARCH; MORTALITY; PAPUA NEW GUINEA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTYPE; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; WAR;

STREPTOCOCCUS PNEUMONIAE;

EID: 84867397168     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03943.x     Document Type: Review

References (91)

1. Wright AE, Morgan WP, Colebrook L, Dodgson RW. Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet 1914; 10: 87-95.
2. Maynard GD. Enquiry into the aetiology, manifestations, and prevention of pneumonia amongst natives on the Rand, recruited from "tropical areas". Publ South Afr Inst Med Res 1913; 1: 1.
3. Heffron R. Pneumonia with special reference to pneumococcal lobar pneumonia. New York, NY: Commonwealth Fund, 1939:446-483, 805-936, 946.
4. Austrian R. Of gold and pneumococci: a history of pneumococcal vaccines in South Africa. Trans Am Clin Climatol Assoc 1977; 89: 141-161.
5. Austrian R. The development of pneumococcal vaccine. Proc Am Phil Soc 1981; 125: 46-51.
6. Kazanjian P. Changing interest among physicians toward pneumococcal vaccination throughout the twentieth century. J Hist Med Allied Sci 2004; 59: 555-587.
7. Sternberg GM. A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. Natl Board Health Bull 1881; 2: 781-783.
8. Malkin HM. The trials and tribulations of George Miller Sternberg (1838-1915): America's first bacteriologist. Perspect Biol Med 1993; 36: 666-678.
9. Pasteur L. Note sur la maladie nouvelle provoqué par la salive d'un enfant mort de la rage. Bull Acad Méd (Paris) 1881; 10: 94-103.
10. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993; 17: 913-924.
11. Austrian R. Maxwell Finland lecture. Random gleanings from a life with the pneumococcus. J Infect Dis 1975; 131: 474-484.
12. Kauffmann F, Lund E, Eddy BE. Proposal for a change in the nomenclature of Diplococcus pneumoniae and a comparison of the Danish and American type designations. Int Bull Bacteriol Nomenclature Taxonomy 1960; 10: 31-40.
13. Fränkel A. Bakteriologische mittheilungen. Zeitschr klin med 1886; 10: 401-461.
14. Fränkel A. Bakteriologische mittheilungen. II. Die micrococcen der pneumonie. Zeitschr klin med 1886; 10: 11.
15. Klemperer G, Klemperer F. Versuche uber immunisirung und heilung bei der pneumokokkeninfection. Berl Klin Wochnschr 1891; 28: 833-835.
16. Huntoon FM. Antipneumococcic serums; purification and concentration. Am J Public Health 1926; 16: 1247-1249.
17. Neufeld F, Händel L. Weitere Untersuchungen über Pneumokokken Heilsera. III Mitteilung Über Vorkommen und Bedeutung atypischer Varietaten des Pneumokokkus. Arb Kaiserlichen Gesundheitsamte (Berlin) 1910; 34: 292-304.
18. Cole R, Dochez AR. Report of studies on pneumonia. Trans Assoc Am Phys 1913; 28: 606-616.
19. Chase A. Magic shots: a human and scientific account of the long and continuing struggle to eradicate infectious diseases by vaccination. New York, NY: William Morrow, 1982.
20. Cecil R, Plummer N. Pneumococcus type I pneumonia, a study of eleven hundred and sixty-one cases, with especial reference to specific therapy. JAMA 1930; 95: 1547-1553.
21. Cecil RL, Austin JH. Results of prophylactic inoculation against pneumococcus in 12, 519 men. J Exp Med 1918; 28: 19-41.
22. Cecil RL, Larsen NP. Clinical and bacteriologic study of one thousand cases of lobar pneumonia. JAMA 1922; 79: 343-349.
23. Cecil RL, Plummer N. Pneumococcus type II pneumonia: a clinical and bacteriologic study of one thousand cases with special reference to serum therapy. JAMA 1930; 98: 779-786.
24. Fennel EA. Prophylactic inoculation against pneumonia: a brief history and the present status of the procedure. JAMA 1918; 71: 2115-2130.
25. Neufeld F, Händel L. Zur Frage der Serumtherapie der Pneumonie und der Wertbestimmung des Pneumokokken-Serums. Berliner Klinische Wochenschrift 1912; 49: 680-683.
26. Dochez AR, Gillespie JL. A biologic classification of pneumococci by means of immunity reactions. JAMA 1913; 61: 727-732.
27. Henrichsen J. Typing of Streptococcus pneumoniae: past, present, and future. Am J Med 1999; 107 (SUPPL 1A): 50S-54S.
28. Lister FS. Specific serological reactions with pneumococci from different sources. Publ South Afr Inst Med Res 1913; 1: 1-108.
29. Ordman D. Pneumonia in the native mine workers of the Witwatersrand goldfields. J Med Assoc S Afr 1931; 5: 108-116.
30. Lister FS. An experimental study of prophylactic inoculation against pneumococcal infection in the rabbit and in man. Publ South Afr Inst Med Res 1916; 8: 231-287.
31. Lister S, Ordman D. Epidemiology of pneumonia on the Witwatersrand goldfields and prevention of pneumonia and other allied acute respiratory diseases in native labourers in South Africa by means of vaccine. Publ South Afr Inst Med Res 1935; 7: 37.
32. Eyler JM. The state of science, microbiology, and vaccines circa 1918. Public Health Rep 2010; 125 (SUPPL 3): 27-36.
33. Chien YW, Klugman KP, Morens DM. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 2010; 202: 1639-1648.
34. Russell FF. Guarding against pneumonia by vaccination. Public Health Rep 1918; 33: 1866-1867.
35. Cecil RL, Vaughan HF. Results of prophylactic vaccination against pneumonia at Camp Wheeler. J Exp Med 1919; 29: 457-483.
36. Dochez AR, Avery OT. Soluble substance of pneumococcus origin in the blood and urine during lobar pneumonia. Proc Soc Exp Biol Med 1917; 14: 126-127.
37. Austrian R, Oswald T. Avery: the wizard of York Avenue. Am J Med 1999; 107 (SUPPL 1A): 7S-11S.
38. Heidelberger M, Avery OT. The soluble specific substances of pneumococcus. J Exp Med 1923; 38: 73-79.
39. Heidelberger M. A "pure" organic chemists downward path. Annu Rev Microbiol 1977; 31: 1-12.
40. Dubos R, Avery OT. Decomposition of the capsular polysaccharide of pneumococcus type II by a bacterial enzyme. J Exp Med 1931; 54: 51-71.
41. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med 1931; 54: 73-89.
42. Schiemann O, Casper W. Sind die spezifisch präcipitabelen Substanzen der 3 Pneumokokkentypen Haptene? Zeitschr Hyg Infëcktionskr 1927; 108: 220-257.
43. Austrian R. Pneumococcus and the Brooklyn connection. Am J Med 1999; 107 (SUPPL 1A): 2S-6S.
44. Francis TJ Jr, Tillett WS. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 1930; 52: 573-585.
45. Francis T. The value of the skin test with type-specific capsular polysaccharide in the serum treatment of Type I pneumococcus pneumonia. J Exp Med 1933; 57: 617-631.
46. Felton LD. Studies on immunizing substances in pneumococci: VII. Response in human beings to antigenic pneumococcus polysaccharides types I and II. Public Health Rep 1938; 53: 1855-1877.
47. Finland M, Ruegsegger JM. Immunization of human subjects with the specific carbohydrates of Type III and the related Type VIII pneumococcus. J Clin Invest 1935; 14: 829-832.
48. Avery OT, Goebel WF. Chemical-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533-542.
49. Felton LD. A study of the isolation and concentration of the specific antibodies of antipneumococcus sera. Boston Med Surg J 1924; 190: 819-825.
50. Finland M, Sutliff WD. Specific cutaneous reactions and circulating antibodies in the course of lobar pneumonia: II. Cases treated with antipneumococcic sera. J Exp Med 1931; 54: 653-667.
51. Parish HJ. A history of immunization. Edinburgh & London: E&S Livingstone Ltd, 1965.
52. Ekwurzel GM, Simmons JS, Dublin LI, Felton LD. Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value of a pneumococcus antigen. Public Health Rep 1938; 53: 1877-1893.
53. English PC. Therapeutic strategies to combat pneumococcal disease: repeated failure of physicians to adopt pneumococcal vaccine, 1900-1945. Perspect Biol Med 1987; 30: 170-185.
54. Smillie WG, Warnock GH, White HJ. A study of a type I pneumococcus epidemic at the state hospital at Worcester, Mass. Am J Public Health 1938; 28: 293-302.
55. Felton LD, Jordan CF, Hesbacher EN, Vaubel EK. Studies on immunizing substances in pneumococci: XII. Comparison of the effect of whole-cell vaccine and of polysaccharide antigen in human beings. Public Health Rep 1941; 56: 1041-1054.
56. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82: 445-465.
57. Heidelberger M. A "pure" organic chemist's downward path: chapter 2 - the years at P. and S. Annu Rev Biochem 1979; 48: 1-21.
58. Klugman KP, Hayden Smith SW, Koornhof HJ. Evidence that prevention of carriage by pneumococcal capsular vaccines may be the mechanism of protection from pneumococcal pneumonia. S Afr J Epidemiol Infect 2011; 26: 221-224.
59. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-2616.
60. Kaufman P. Pneumonia in old age. Arch Intern Med 1947; 79: 518-531.
61. Sell SH, Wright PF, Vaughn WK, Thompson J, Schiffman G. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis 1981; 3 (suppl): S97-S107.
62. Heidelberger M, MacLeod CM, DiLapi MM. The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J Exp Med 1948; 88: 369-372.
63. US Office of Technology Assessment. A review of selected federal vaccine and immunization policies: based on case studies of pneumococcal vaccine. Washington, DC: Office of Technology Assessment, September 1979:1-208.
64. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759-771.
65. Austrian R, Douglas RM, Schiffman G et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Phys 1976; 89: 184-194.
66. Grabenstein JD, Pittman PR, Greenwood JT, Engler RJM. Immunization to protect the U.S. Armed Forces: heritage, current practice, prospects. Epidemiol Rev 2006; 28: 3-26.
67. Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J Infect Dis 1977; 136 (suppl): S38-S42.
68. Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. Bethesda, MD: National Institute of Allergy & Infectious Diseases 1980: 184-194.
69. Riley ID, Andrews M, Howard R et al. Immunization with polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977; 1: 1338-1341.
70. Douglas RM, Riley ID. Pneumococcal disease and its prevention with polyvalent pneumococcal polysaccharide vaccines: a review. Aust NZ J Med 1979; 9: 327-338.
71. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986; 2: 877-881.
72. Riley ID, Lehmann D, Alpers MP. Pneumococcal vaccine trials in Papua New Guinea: relationships between epidemiology of pneumococcal infection and efficacy of vaccine. Rev Infect Dis 1991; 13 (SUPPL 6): S535-S541.
73. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. MMWR 1978; 27: 25-26.
74. Hilleman MR, Carlson AJ Jr, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981; 3 (suppl): S31-S42.
75. Robbins JB, Austrian R, Lee CJ et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1136-1159.
76. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo-controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol 1986; 22: 807-813.
77. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine usage - United States. MMWR 1984; 33: 273-276.
78. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-195.
79. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152: 361-376.
80. Schneerson R, Robbins JB, Chu C et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 1984; 45: 582-591.
81. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990; 161: 821-832.
82. Robbins JB, Schneerson R, Anderson P, Smith DH. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: impact on public health and implications for other polysaccharide-based vaccines. JAMA 1996; 276: 1181-1185.
83. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
84. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-768.
85. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-946.
86. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, Issue 1. DOI: 10.1002/14651858. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000422/frame.html Full text at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000422/pdf_fs.html
87. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58. erratum 1038.
88. Andrews R, Moberley SA. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009; 180: 18-19. (editorial).
89. Austrian R. Pneumococcal vaccine and pneumococcal pneumonia. Ann Intern Med 1988; 108: 762. (letter)
90. Hak E, Grobbee DE, Sanders EAM et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383.
91. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23: 407-413.